Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Discov ; 6(12): 1366-1381, 2016 12.
Article in English | MEDLINE | ID: mdl-27683557

ABSTRACT

Programmed death-1 (PD-1) is a coinhibitory receptor that downregulates the activity of tumor-infiltrating lymphocytes (TIL) in cancer and of virus-specific T cells in chronic infection. The molecular mechanisms driving high PD-1 expression on TILs have not been fully investigated. We demonstrate that TGFß1 enhances antigen-induced PD-1 expression through SMAD3-dependent, SMAD2-independent transcriptional activation in T cells in vitro and in TILs in vivo The PD-1hi subset seen in CD8+ TILs is absent in Smad3-deficient tumor-specific CD8+ TILs, resulting in enhanced cytokine production by TILs and in draining lymph nodes and antitumor activity. In addition to TGFß1's previously known effects on T-cell function, our findings suggest that TGFß1 mediates T-cell suppression via PD-1 upregulation in the tumor microenvironment (TME). They highlight bidirectional cross-talk between effector TILs and TGFß-producing cells that upregulates multiple components of the PD-1 signaling pathway to inhibit antitumor immunity. SIGNIFICANCE: Engagement of the coinhibitory receptor PD-1 or its ligand, PD-L1, dramatically inhibits the antitumor function of TILs within the TME. Our findings represent a novel immunosuppressive function of TGFß and demonstrate that TGFß1 allows tumors to evade host immune responses in part through enhanced SMAD3-mediated PD-1 expression on TILs. Cancer Discov; 6(12); 1366-81. ©2016 AACRThis article is highlighted in the In This Issue feature, p. 1293.


Subject(s)
CD8-Positive T-Lymphocytes/metabolism , Neoplasms/immunology , Programmed Cell Death 1 Receptor/genetics , Smad3 Protein/metabolism , Transforming Growth Factor beta1/metabolism , Animals , Cell Line, Tumor , Cytokines/metabolism , Drug Resistance, Neoplasm , Humans , Jurkat Cells , Lymphocytes, Tumor-Infiltrating/metabolism , Mice , Neoplasms/metabolism , Programmed Cell Death 1 Receptor/metabolism , Signal Transduction , Tumor Microenvironment
2.
PLoS Pathog ; 10(5): e1004082, 2014 May.
Article in English | MEDLINE | ID: mdl-24788318

ABSTRACT

Innate immune sensing of viral infection results in type I interferon (IFN) production and inflammasome activation. Type I IFNs, primarily IFN-α and IFN-ß, are produced by all cell types upon virus infection and promote an antiviral state in surrounding cells by inducing the expression of IFN-stimulated genes. Type I IFN production is mediated by Toll-like receptor (TLR) 3 in HCV infected hepatocytes. Type I IFNs are also produced by plasmacytoid dendritic cells (pDC) after sensing of HIV and HCV through TLR7 in the absence of productive pDC infection. Inflammasomes are multi-protein cytosolic complexes that integrate several pathogen-triggered signaling cascades ultimately leading to caspase-1 activation and generation pro-inflammatory cytokines including interleukin (IL)-18 and IL-1ß. Here, we demonstrate that HIV and HCV activate the inflammasome, but not Type I IFN production, in monocytes and macrophages in an infection-independent process that requires clathrin-mediated endocytosis and recognition of the virus by distinct endosomal TLRs. Knockdown of each endosomal TLR in primary monocytes by RNA interference reveals that inflammasome activation in these cells results from HIV sensing by TLR8 and HCV recognition by TLR7. Despite its critical role in type I IFN production by pDCs stimulated with HIV, TLR7 is not required for inflammasome activation by HIV. Similarly, HCV activation of the inflammasome in monocytes does not require TLR3 or its downstream signaling adaptor TICAM-1, while this pathway leads to type I IFN in infected hepatocytes. Monocytes and macrophages do not produce type I IFN upon TLR8 or TLR7 sensing of HIV or HCV, respectively. These findings reveal a novel infection-independent mechanism for chronic viral induction of key anti-viral programs and demonstrate distinct TLR utilization by different cell types for activation of the type I IFN vs. inflammasome pathways of inflammation.


Subject(s)
HIV-1/immunology , Hepacivirus/immunology , Inflammasomes/metabolism , Interferon Type I/metabolism , Macrophages/metabolism , Monocytes/metabolism , Toll-Like Receptors/physiology , Cells, Cultured , Cytokines/metabolism , Endocytosis/immunology , Endosomes/immunology , Endosomes/metabolism , HIV Infections/immunology , HIV Infections/metabolism , HIV-1/physiology , Hep G2 Cells , Hepacivirus/physiology , Hepatitis C/immunology , Hepatitis C/metabolism , Humans , Macrophages/immunology , Macrophages/virology , Monocytes/immunology , Monocytes/virology , Virus Internalization
SELECTION OF CITATIONS
SEARCH DETAIL
...